Planet 13 Holdings Inc.

Planet 13 Holdings Inc. operates as a vertically integrated cannabis company, overseeing the cultivation, manufacturing, distribution, and marketing of cannabis and infused products. Its primary focus is serving both the medical and recreational marijuana markets within Nevada, U.S. Beyond its core cannabis activities, the company manages licensed cannabis dispensaries, a retail store for general merchandise, and an event space. Planet 13 further expands its portfolio by owning and operating hospitality venues, including Trece Eatery + Spirits, a coffee shop, and a pizzeria. Additionally, it offers consulting, educational resources, and various convenience services. The company is responsible for producing a diverse range of cannabis items such as chocolates, gummies, sparkling beverages, vapes, concentrates, and raw flower, which are marketed under its proprietary brands: TRENDI, Leaf & Vine, Dreamland, HaHa, and Medizin. The corporate headquarters for Planet 13 Holdings Inc. are situated in Las Vegas, Nevada.

Planet 13 Holdings Inc. trades as PLTH.CN on CNQ. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in CAD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $105.19M of revenue and -$65.04M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Planet 13 Holdings Inc. can be compared against peers such as BioNxt Solutions Inc., The Cannabist Company Holdings Inc., C21 Investments Inc., Decibel Cannabis Company Inc., iAnthus Capital Holdings, Inc., InnoCan Pharma Corporation.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $65.72M, beta of 1.74, and return on equity of -127.5%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

PLTH.CN currently shows total debt of $54.25M and beta of 1.74. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.planet13holdings.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.